Exclusive: GV’s David Schenkein turns to a familiar face at Novartis for his latest recruit as entrepreneur-in-residence
David Schenkein has added a new member to GV’s still quite exclusive club of biotech CEOs-in-waiting. And this time the Google Ventures player is turning to someone he’d worked with for years at Agios, the company he built from a white sheet of paper.
Schenkein recruited Kevin Marks out of NIBR, where he’s been working as head of the oncology discovery group. But before joining Jay Bradner’s discovery crew in the fall of 2020, Marks had spent close to 12 years at Agios, including a broad swath of time that overlapped with Schenkein’s decade-long run as CEO, which was later superseded by an ongoing stretch as chairman of the board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.